Faeth Appoints Zymeworks R&D Head Adam Schayowitz to Board
Faeth appointed Adam Schayowitz, Zymeworks’ head of research and development, to its board of directors. Faeth said he brings nearly 20 years of oncology drug development experience.
Related stories
IIFL Capital launches Sagility block deal worth up to $249.6 million
The offer price could be around Rs 42.45 per share, at a discount to Sagility's October 29 close. Sagility B.V. is expected to be the seller, sources told Moneycontrol.
M impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
DoorDash to Acquire Instacart in $17 Billion Deal
DoorDash has agreed to acquire Maplebear, Instacart’s parent, in a $17 billion deal. The headline also says quarterly results topped views.
H impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
Summi Group Delays Publication of FY26 Annual Results
M impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
Xsolla Acquires GamePix to Expand Game Distribution
Xsolla said it acquired web games platform GamePix to expand web and AI-created game distribution.
M impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
Dynamix Plans Liquidation After Business Combination Fails
Dynamix plans to liquidate after failing to complete its business combination.
M impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
Dynamix Corp to Cease Operations Except Winding Up
M impact | EQUITY | Oct 29, 2026, 03:30 PM UTC